Novavax

NVAXNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$1.717 B

$10.41 +2.97%

Close of 21 Sept 2026

Revenue

$1.12B

#1463 by revenue

Earnings

$440.3M

#670 by earnings

Shares outstanding

164,945,726

Latest filing cover page

P/E ratio

3.9

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#36Vir BiotechnologyVIR$1.84B
#37Hemab TherapeuticsCOAG$1.77B
#38NovavaxNVAX$1.72B
#39ImmunocoreIMCR$1.66B
#40Inhibrx BiosciencesINBX$1.65B

What if Novavax were worth as much as…

Open the what-if tool →

Gold $30.3T

$183,539.49

Per share 17,631× higher

Bitcoin $1.72T

$10,426.48

Per share 1,002× higher

Nvidia $5.48T

$33,222.19

Per share 3,191× higher

Or at a round number

$5.00B $10.0B $20.0B $50.0B

Where these numbers come from

Share counts and financials for Novavax are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.